Molecular Partners (MOLN) announced it has entered into an agreement with Eckert & Ziegler to enable the development and manufacturing of Radio-DARPin therapeutics. Under the non-exclusive agreement, Eckert & Ziegler will support Molecular Partners with a range of services covering development activities for Radio-DARPins with Actinium-225 and Lutetium-177 payloads. The development agreement will leverage Eckert & Ziegler’s laboratories, including its newly established Alpha Laboratory in Berlin, Germany, dedicated exclusively to work with alpha emitters.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MOLN:
- Molecular Partners Unveils First Human Data for DLL3-Targeting Radio-DARPin MP0712 at TWC 2026
- Molecular Partners presents first imaging, dosimetry data of MP0712
- Molecular Partners initiated with a Buy at H.C. Wainwright
- Molecular Partners Launches New Clinical Trials and Maps 2026 Milestones Ahead of J.P. Morgan Healthcare Conference
- Molecular Partners provided update on latest progress, 2026 milestones